TP53INP2

Summary

TP53INP2 (tumor protein p53 inducible nuclear protein 2, HGNC:16104) is a protein-coding gene on chromosome 20q11.22, encoding Tumor protein p53-inducible nuclear protein 2 (Q8IXH6). Dual regulator of transcription and autophagy.

The protein encoded by this gene promotes autophagy and is essential for proper autophagosome formation and processing. In addition, the encoded protein can enhance rDNA transcription by helping in the assembly of the POLR1/RNA polymerase I preinitiation complex. Finally, this protein serves as a transcriptional activator for some genes.

Source: NCBI Gene 58476 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 15 total
• MANE Select transcript: NM_021202

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16104
Approved symbol	TP53INP2
Name	tumor protein p53 inducible nuclear protein 2
Location	20q11.22
Locus type	gene with protein product
Status	Approved
Aliases	FLJ21759, FLJ23500, DKFZp434B2411, DKFZp434O0827, dJ1181N3.1, PINH, DOR
Ensembl gene	ENSG00000078804
Ensembl biotype	protein_coding
OMIM	617549
Entrez	58476

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 22 protein_coding

ENST00000374809, ENST00000374810, ENST00000414082, ENST00000451665, ENST00000894582, ENST00000894583, ENST00000894584, ENST00000894585, ENST00000894586, ENST00000894587, ENST00000894588, ENST00000894589, ENST00000894590, ENST00000894591, ENST00000894592, ENST00000894593, ENST00000894594, ENST00000894595, ENST00000894596, ENST00000894597, ENST00000894598, ENST00000962433

RefSeq mRNA: 4 — MANE Select: NM_021202 NM_001329429, NM_001329430, NM_001329431, NM_021202

CCDS: CCDS13240

Canonical transcript exons

ENST00000374810 — 5 exons

Exon	Start	End
ENSE00000661451	34709236	34709524
ENSE00001334475	34705358	34705474
ENSE00001464719	34708691	34708863
ENSE00001529736	34704344	34704512
ENSE00003842542	34710058	34713436

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.86.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 55.4827 / max 2442.3369, expressed in 1801 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
184241	50.0518	1789
184255	3.0666	890
184242	1.5909	699
184245	0.5341	232
184256	0.2393	103

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
inferior vagus X ganglion	UBERON:0005363	99.86	gold quality
lateral globus pallidus	UBERON:0002476	99.70	gold quality
globus pallidus	UBERON:0001875	99.69	gold quality
medial globus pallidus	UBERON:0002477	99.69	gold quality
subthalamic nucleus	UBERON:0001906	99.68	gold quality
medulla oblongata	UBERON:0001896	99.63	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	99.62	gold quality
spinal cord	UBERON:0002240	99.61	gold quality
ventral tegmental area	UBERON:0002691	99.58	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.55	gold quality
superior vestibular nucleus	UBERON:0007227	99.55	gold quality
dorsal plus ventral thalamus	UBERON:0001897	99.54	gold quality
lateral nuclear group of thalamus	UBERON:0002736	99.31	gold quality
midbrain	UBERON:0001891	99.29	gold quality
substantia nigra pars compacta	UBERON:0001965	99.27	gold quality
substantia nigra	UBERON:0002038	99.26	gold quality
pons	UBERON:0000988	99.07	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.96	gold quality
left ventricle myocardium	UBERON:0006566	98.81	gold quality
amygdala	UBERON:0001876	98.77	gold quality
putamen	UBERON:0001874	98.53	gold quality
hypothalamus	UBERON:0001898	98.36	gold quality
Ammon’s horn	UBERON:0001954	98.09	gold quality
parietal lobe	UBERON:0001872	97.86	gold quality
kidney epithelium	UBERON:0004819	97.86	gold quality
pharyngeal mucosa	UBERON:0000355	97.78	gold quality
postcentral gyrus	UBERON:0002581	97.75	gold quality
lower esophagus mucosa	UBERON:0035834	97.75	gold quality
saphenous vein	UBERON:0007318	97.39	gold quality
body of tongue	UBERON:0011876	97.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.19

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

220 targeting TP53INP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-515-5P	99.92	69.82	2343

Literature-anchored findings (GeneRIF, showing 21)

• TP53INP2 is a novel gene involved in the autophagy of mammalian cells. (PMID:19056683)
• Alternative splicing of an exon in the 5’ untranslated region of a gene termed TP53INP2 is a key event downstream of hnRNP A2 that is necessary for cells to invade the extracellular matrix. (PMID:19934309)
• DOR plays an important role in thyroid hormone-mediated osteoblast differentiation, and a DOR SNP associates with plasma osteocalcin in men. (PMID:21467300)
• Mutation of conserved hydrophobic residues in region 1 of TP53inp2 reduces transcriptional activity, and blocks nuclear exit and autophagic activity under autophagy-activated conditions. (PMID:22470510)
• nucleolus integrity is not essential for both DOR nucleo-cytoplasmic shuttling and DOR function on basal autophagy (PMID:22750142)
• TP53INP2 promotes ribosome biogenesis through facilitating rRNA synthesis at the nucleolus (PMID:27172002)
• The results reveal the association of TP53INP2-related basal autophagy with cell growth and malignant progression of human liposarcoma. (PMID:28131096)
• We conducted a replication study using a dataset outside of the Challenge, and found the association between TP53INP2 and ER-negative breast cancer was significant (p = 5.07x10-3). Expression of HP (16q22.2) showed a suggestive association with ER-negative breast cancer in the discovery phase (Z = 4.30, p = 1.70x10-5) although the association was not significant after Bonferroni adjustment. (PMID:28957356)
• TP53INP2 modulates adipogenesis through autophagy-dependent sequestration of GSK3beta into late endosomes and beta catenin activation, regulating adiposity. (PMID:29593329)
• TP53INP2 interacted directly with ATG7 to form a LC3B-TP53INP2-ATG7 complex in the cytoplasm. (PMID:30767704)
• Tp53inp2 is an atypical mRNA that regulates axon growth by enhancing NGF-TrkA signaling in a translation-independent manner. (PMID:30853298)
• A screen of cancer cell lines showed that those with higher protein levels of TP53INP2 are more prone to TRAIL-induced apoptosis, making TP53INP2 a potential predictive marker of cancer cell responsiveness to TRAIL treatment. These findings uncover a novel mechanism for the regulation of caspase-8 ubiquitination and reveal TP53INP2 as an important regulator of the death receptor pathway. (PMID:30979779)
• Results showed that TP53INP2 interacts with ubiquitin and ubiquitinated proteins through the ubiquitin-interacting motif (UIM). Moreover, overexpression of TP53INP2 lacking the UIM in cells leads to massive accumulation of ubiquitinated proteins and sensitizes the cells to apoptosis under stressed conditions. (PMID:31155706)
• The bifunctional role of TP53INP2 in transcription and autophagy. (PMID:31931658)
• Dysregulation in the expression of (lncRNA-TSIX, TP53INP2 mRNA, miRNA-1283) in spinal cord injury. (PMID:32535070)
• Overexpression of TP53INP2 Promotes Apoptosis in Clear Cell Renal Cell Cancer via Caspase-8/TRAF6 Signaling Pathway. (PMID:35615533)
• TP53INP2 Contributes to TGF-beta2-Induced Autophagy during the Epithelial-Mesenchymal Transition in Posterior Capsular Opacification Development. (PMID:35954230)
• Inactivation of ZSCAN18 by promoter hypermethylation drives the proliferation via attenuating TP53INP2-mediated autophagy in gastric cancer cells. (PMID:36650573)
• Cytoplasmic Expression of TP53INP2 Modulated by Demethylase FTO and Mutant NPM1 Promotes Autophagy in Leukemia Cells. (PMID:36675134)
• TP53INP2 modulates the malignant progression of colorectal cancer by reducing the inactive form of beta-catenin. (PMID:37995453)
• TP53INP2-dependent activation of muscle autophagy ameliorates sarcopenia and promotes healthy aging. (PMID:38545813)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tp53inp2	ENSDARG00000088178
danio_rerio		ENSDARG00000109769
mus_musculus	Trp53inp2	ENSMUSG00000038375
rattus_norvegicus	Tp53inp2	ENSRNOG00000018225

Paralogs (1): TP53INP1 (ENSG00000164938)

Protein

Protein identifiers

Tumor protein p53-inducible nuclear protein 2 — Q8IXH6 (reviewed: Q8IXH6)

Alternative names: Diabetes and obesity-regulated gene, p53-inducible protein U

All UniProt accessions (3): Q8IXH6, Q5JX65, Q5JX66

UniProt curated annotations — full annotation on UniProt →

Function. Dual regulator of transcription and autophagy. Positively regulates autophagy and is required for autophagosome formation and processing. May act as a scaffold protein that recruits MAP1LC3A, GABARAP and GABARAPL2 and brings them to the autophagosome membrane by interacting with VMP1 where, in cooperation with the BECN1-PI3-kinase class III complex, they trigger autophagosome development. Acts as a transcriptional activator of THRA.

Subunit / interactions. Interacts with VMP1, GABARAP, GABARAPL1, GABARAPL2, MAP1LC3A, MAP1LC3B, MAP1LC3C and THRA.

Subcellular location. Cytoplasm. Cytosol. Nucleus. PML body. Cytoplasmic vesicle. Autophagosome.

Domain organisation. The LC3 interacting region (LIR) motif mediates interaction with GABARAP, GABARAPL1, GABARAPL2, MAP1LC3A, MAP1LC3B and MAP1LC3C.

RefSeq proteins (4): NP_001316358, NP_001316359, NP_001316360, NP_067025* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029431	TP53INP	Family

Pfam: PF14839

UniProt features (14 total): compositionally biased region 4, region of interest 3, modified residue 2, strand 2, chain 1, sequence conflict 1, short sequence motif 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
8T33	X-RAY DIFFRACTION	1.6
7YO9	X-RAY DIFFRACTION	1.75
8T36	X-RAY DIFFRACTION	1.85
8T35	X-RAY DIFFRACTION	1.9
8T32	X-RAY DIFFRACTION	2.05
8T31	X-RAY DIFFRACTION	2.1
8T4T	X-RAY DIFFRACTION	2.36

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IXH6-F1	64.65	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 136, 14

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 252 (showing top): CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN, GOBP_VACUOLE_ORGANIZATION, PEREZ_TP63_TARGETS, NIKOLSKY_BREAST_CANCER_20Q11_AMPLICON, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, CREBP1_Q2, TAL1ALPHAE47_01, CACCAGC_MIR138, CTATGCA_MIR153, AAAYRNCTG_UNKNOWN, CAGCTG_AP4_Q5, GOBP_MACROAUTOPHAGY, CREB_Q4

GO Biological Process (9): autophagosome assembly (GO:0000045), osteoblast differentiation (GO:0001649), tissue homeostasis (GO:0001894), ubiquitin-dependent protein catabolic process (GO:0006511), intracellular protein localization (GO:0008104), positive regulation of DNA-templated transcription (GO:0045893), negative regulation of protein localization (GO:1903828), autophagy (GO:0006914), macroautophagy (GO:0016236)

GO Molecular Function (2): ubiquitin binding (GO:0043130), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), autophagosome (GO:0005776), cytosol (GO:0005829), PML body (GO:0016605), cytoplasmic vesicle (GO:0031410), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
cellular anatomical structure	2
Atg12 activating enzyme activity	1
protein-phosphatidylethanolamide deconjugating activity	1
Atg12 conjugating enzyme activity	1
Atg12 ligase activity	1
organelle assembly	1
Atg1/ULK1 kinase complex assembly	1
autophagosome organization	1
ossification	1
cell differentiation	1
multicellular organismal-level homeostasis	1
anatomical structure homeostasis	1
protein ubiquitination	1
modification-dependent protein catabolic process	1
macromolecule localization	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
intracellular protein localization	1
regulation of protein localization	1
negative regulation of biological process	1
catabolic process	1
transmembrane transport	1
process utilizing autophagic mechanism	1
autophagosome assembly	1
autophagy	1
ubiquitin-like protein binding	1
binding	1
intracellular membrane-bounded organelle	1
vacuole	1
nuclear body	1
intracellular vesicle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

412 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TP53INP2	GABARAPL2	P60520	682
TP53INP2	F5GZY7	F5GZY7	682
TP53INP2	VMP1	Q96GC9	664
TP53INP2	NUPR2	A6NF83	628
TP53INP2	MAP1LC3C	Q9BXW4	591
TP53INP2	GABARAP	O95166	583
TP53INP2	MAP1A	P78559	460
TP53INP2	NTRK1	P04629	412
TP53INP2	ATG16L1	Q676U5	363
TP53INP2	NRG2	O14511	360
TP53INP2	C14orf119	Q9NWQ9	350
TP53INP2	TP53I11	O14683	349
TP53INP2	CD300C	Q08708	324
TP53INP2	ATG7	O95352	322
TP53INP2	SPNS1	Q9H2V7	310

IntAct

6 interactions, top by confidence:

A	B	Type	Score
Map1lc3a	TP53INP2	psi-mi:“MI:0403”(colocalization)	0.460
Map1lc3a	TP53INP2	psi-mi:“MI:0915”(physical association)	0.460
MAP1LC3A	TP53INP2	psi-mi:“MI:0407”(direct interaction)	0.440
GABARAPL2	TP53INP2	psi-mi:“MI:0915”(physical association)	0.370
RACK1	RPS3A	psi-mi:“MI:0914”(association)	0.350

BioGRID (10): MAP1LC3A (Affinity Capture-Western), TP53INP2 (Affinity Capture-Western), GABARAPL2 (Affinity Capture-Western), GABARAPL2 (Two-hybrid), TP53INP2 (Affinity Capture-Western), TP53INP2 (Two-hybrid), TP53INP2 (Affinity Capture-MS), TP53INP2 (Affinity Capture-Western), TP53INP2 (Protein-peptide), TP53INP2 (Protein-peptide)

ESM2 similar proteins: A2A9T0, A2AEV7, A2AHG0, A5PKL7, A6H7I7, A6NCL7, A6NKL6, B8ZZ34, D3ZZN9, J3QNX5, O60299, Q0PHV7, Q1W6H9, Q2KJ38, Q2M3G4, Q2M3V2, Q3LUD4, Q3SX20, Q4KLY2, Q4KMQ1, Q4QRD7, Q53LP3, Q58DG5, Q5RKJ0, Q5SW24, Q6DG50, Q6NUJ5, Q6NY19, Q6PJ61, Q6ZW31, Q7TN08, Q7TNF9, Q80X91, Q8BLS7, Q8CHM3, Q8IX07, Q8IXH6, Q8K1Q4, Q8R184, Q8TAY7

Diamond homologs: Q80YE2, Q8CFU8, Q8CHM3, Q8IXH6, Q96A56, Q9QXE4

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
TP53INP2	up-regulates	GABARAPL2	binding
TP53INP2	up-regulates	MAP1LC3A	binding
GRK2	“down-regulates activity”	TP53INP2	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

15 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	10
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

592 predictions. Top by Δscore:

Variant	Effect	Δscore
20:34704509:CCAGG:C	donor_loss	1.0000
20:34704511:AGGTG:A	donor_loss	1.0000
20:34704513:G:C	donor_loss	1.0000
20:34708859:GCCGG:G	donor_gain	1.0000
20:34709523:GG:G	donor_gain	1.0000
20:34709524:GG:G	donor_gain	1.0000
20:34710056:A:AG	acceptor_gain	1.0000
20:34710056:AG:A	acceptor_gain	1.0000
20:34710056:AGG:A	acceptor_gain	1.0000
20:34710057:G:GG	acceptor_gain	1.0000
20:34710057:GG:G	acceptor_gain	1.0000
20:34710057:GGG:G	acceptor_gain	1.0000
20:34704513:G:GG	donor_gain	0.9900
20:34708860:CCGG:C	donor_loss	0.9900
20:34708861:CGG:C	donor_loss	0.9900
20:34708862:GG:G	donor_gain	0.9900
20:34708863:GG:G	donor_gain	0.9900
20:34708863:GGTGA:G	donor_loss	0.9900
20:34708869:GCC:G	donor_gain	0.9900
20:34709350:C:CA	acceptor_gain	0.9900
20:34709525:G:GG	donor_gain	0.9900
20:34709525:GT:G	donor_loss	0.9900
20:34709526:T:A	donor_loss	0.9900
20:34710052:TCACA:T	acceptor_loss	0.9900
20:34710053:CACAG:C	acceptor_loss	0.9900
20:34710054:A:AG	acceptor_gain	0.9900
20:34710054:ACAG:A	acceptor_gain	0.9900
20:34710054:ACAGG:A	acceptor_gain	0.9900
20:34710055:CAGG:C	acceptor_loss	0.9900
20:34710056:A:C	acceptor_loss	0.9900

AlphaMissense

1415 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:34709407:T:C	L99P	1.000
20:34709413:T:A	I101N	1.000
20:34709322:T:A	W71R	0.999
20:34709322:T:C	W71R	0.999
20:34709346:T:C	F79L	0.999
20:34709348:T:A	F79L	0.999
20:34709348:T:G	F79L	0.999
20:34709410:T:A	L100H	0.999
20:34709410:T:C	L100P	0.999
20:34709413:T:G	I101S	0.999
20:34709419:A:G	H103R	0.999
20:34709420:C:A	H103Q	0.999
20:34709420:C:G	H103Q	0.999
20:34709424:A:C	S105R	0.999
20:34709426:C:A	S105R	0.999
20:34709426:C:G	S105R	0.999
20:34709429:G:A	M106I	0.999
20:34709429:G:C	M106I	0.999
20:34709429:G:T	M106I	0.999
20:34709431:C:T	S107F	0.999
20:34709324:G:C	W71C	0.998
20:34709324:G:T	W71C	0.998
20:34709347:T:C	F79S	0.998
20:34709401:A:T	E97V	0.998
20:34709416:A:T	E102V	0.998
20:34709417:G:C	E102D	0.998
20:34709417:G:T	E102D	0.998
20:34709421:C:A	P104T	0.998
20:34709421:C:T	P104S	0.998
20:34709422:C:A	P104H	0.998

dbSNP variants (sampled 300 via entrez): RS1000132520 (20:34706772 G>A), RS1000496353 (20:34709800 C>G,T), RS1000560781 (20:34704662 A>T), RS1000653265 (20:34709637 G>A), RS1001015495 (20:34711361 T>A,G), RS1001177544 (20:34713216 G>A,T), RS1001464843 (20:34711057 A>C), RS1001804506 (20:34708399 G>A,C), RS1001831926 (20:34706339 T>C), RS1001855495 (20:34708040 C>A,T), RS1002073404 (20:34706854 T>A), RS1002167141 (20:34711628 TC>T), RS1002325584 (20:34711226 C>T), RS1002522794 (20:34710625 C>T), RS1002748019 (20:34704339 C>A,T)

Disease associations

OMIM: gene MIM:617549 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST003372_40	Glomerular filtration rate (creatinine)	2.000000e-09
GCST004292_39	Glomerular filtration rate (creatinine)	2.000000e-13
GCST005956_31	Waist-to-hip ratio adjusted for BMI	8.000000e-08
GCST005958_16	Waist-to-hip ratio adjusted for BMI (age >50)	6.000000e-06
GCST005962_40	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	3.000000e-08
GCST007344_40	Estimated glomerular filtration rate	1.000000e-11
GCST007856_83	Colorectal cancer or advanced adenoma	3.000000e-07
GCST008103_149	Bipolar disorder	3.000000e-06
GCST008971_73	Urate levels	3.000000e-09
GCST010135_33	Oily fish consumption	7.000000e-09
GCST010140_23	Pork consumption	7.000000e-09
GCST010142_10	Fish- and plant-related diet	8.000000e-12

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004531	urate measurement
EFO:0008111	diet measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases methylation, affects expression, decreases expression, decreases methylation, increases expression	4
Aflatoxin B1	increases methylation, affects expression, increases expression	4
Cyclosporine	affects expression, decreases expression	3
sodium arsenite	affects methylation, increases expression	2
perfluorooctane sulfonic acid	decreases expression	2
(+)-JQ1 compound	increases expression	2
Acetaminophen	increases expression	2
Air Pollutants	affects expression, increases abundance, decreases expression	2
Estradiol	affects expression, decreases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
perfluorooctanoic acid	decreases expression	1
resorcinol	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
nutlin 3	affects cotreatment, increases expression	1
trans-10,cis-12-conjugated linoleic acid	increases expression	1
abrine	increases expression	1
PCI 5002	affects cotreatment, increases expression	1
Rosiglitazone	decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Aldehydes	decreases expression	1
Arsenic	decreases expression	1
Benzene	increases expression	1

Cellosaurus cell lines

4 cell lines: 3 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3JX	Abcam HEK293T TP53INP2 KO	Transformed cell line	Female
CVCL_TT46	HAP1 TP53INP2 (-) 1	Cancer cell line	Male
CVCL_TT47	HAP1 TP53INP2 (-) 2	Cancer cell line	Male
CVCL_TT48	HAP1 TP53INP2 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.